BR112022001037A2 - Métodos para tratamento ou prevenção de cânceres envolvendo a administração de agentes receptores anti-ccr5 - Google Patents

Métodos para tratamento ou prevenção de cânceres envolvendo a administração de agentes receptores anti-ccr5

Info

Publication number
BR112022001037A2
BR112022001037A2 BR112022001037A BR112022001037A BR112022001037A2 BR 112022001037 A2 BR112022001037 A2 BR 112022001037A2 BR 112022001037 A BR112022001037 A BR 112022001037A BR 112022001037 A BR112022001037 A BR 112022001037A BR 112022001037 A2 BR112022001037 A2 BR 112022001037A2
Authority
BR
Brazil
Prior art keywords
administration
treating
methods
ccr5 receptor
preventing cancers
Prior art date
Application number
BR112022001037A
Other languages
English (en)
Portuguese (pt)
Inventor
Denis Burger
Scott Kelly
Original Assignee
Cytodyn Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytodyn Inc filed Critical Cytodyn Inc
Publication of BR112022001037A2 publication Critical patent/BR112022001037A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
BR112022001037A 2019-08-02 2020-07-31 Métodos para tratamento ou prevenção de cânceres envolvendo a administração de agentes receptores anti-ccr5 BR112022001037A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962882353P 2019-08-02 2019-08-02
US202063047693P 2020-07-02 2020-07-02
PCT/US2020/044616 WO2021026028A1 (en) 2019-08-02 2020-07-31 Methods for treating or preventing cancers involving the administration of anti-ccr5 receptor agents

Publications (1)

Publication Number Publication Date
BR112022001037A2 true BR112022001037A2 (pt) 2022-06-07

Family

ID=72193578

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022001037A BR112022001037A2 (pt) 2019-08-02 2020-07-31 Métodos para tratamento ou prevenção de cânceres envolvendo a administração de agentes receptores anti-ccr5

Country Status (9)

Country Link
US (1) US20220298249A1 (https=)
EP (1) EP4007603A1 (https=)
JP (1) JP2022542524A (https=)
CN (1) CN114502594A (https=)
AU (1) AU2020324948A1 (https=)
BR (1) BR112022001037A2 (https=)
CA (1) CA3146474A1 (https=)
MX (1) MX2022001411A (https=)
WO (1) WO2021026028A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023532019A (ja) * 2020-06-23 2023-07-26 マドン アドバイザーズ エルエルシー 抗ｃｃｒ５モノクローナル抗体ベースの組成物および方法
WO2025250666A1 (en) * 2024-05-29 2025-12-04 Cytodyn, Inc. Methods of treating cancer and inflammation-related diseases with leronlimab

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6458355B1 (en) 1998-01-22 2002-10-01 Genentech, Inc. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
US7122185B2 (en) 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
CA2616189C (en) 2005-07-22 2019-03-26 Progenics Pharmaceuticals, Inc. Methods for reducing viral load in hiv-1-infected patients
MX2008014296A (es) * 2006-06-12 2009-03-06 Pfizer Prod Inc Antagonista de ccr5 para mejorar la restitucion inmunitaria y tratar la infeccion oportunista en pacientes con vih.
CA2939464A1 (en) * 2014-02-18 2015-08-27 Cytodyn Inc. Use of anti-ccr5 antibodies in graft versus host disease
CN107847514A (zh) 2015-06-23 2018-03-27 西托戴恩股份有限公司 炎症、癌症、自身免疫和其它病症中ccl5配体结合ccr5受体的抑制作用和ccr5/ccl5轴信号传导的改变
US20190016810A1 (en) * 2017-05-11 2019-01-17 Cytodyn Inc. Methods for treating or preventing graft-versus-host disease involving the administration of anti-ccr5 receptor agents

Also Published As

Publication number Publication date
EP4007603A1 (en) 2022-06-08
JP2022542524A (ja) 2022-10-04
WO2021026028A1 (en) 2021-02-11
CA3146474A1 (en) 2021-02-11
AU2020324948A1 (en) 2022-02-17
MX2022001411A (es) 2022-03-25
CN114502594A (zh) 2022-05-13
US20220298249A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
CY1124791T1 (el) Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων
PH12019501663A1 (en) Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
MX2017015811A (es) Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
PH12018500642A1 (en) Anti-garp antibody
MX2019008207A (es) Métodos para tratar el cáncer con anticuerpos anti-pd-1.
MX387530B (es) Anticuerpo anti-receptor cgrp para usarse en tratar o prevenir dolor de cabeza por migraña.
BR112014018481A2 (pt) anticorpo monoclonal ou policlonal ou um fragmento de ligação a antígeno do mesmo, polinucleotídeo, anticorpo monoclonal, vetor, hibridoma, anticorpo, hibridoma 5166-2 e/ou 5166-9, anticorpo ou fragmento de ligação a antígeno, composição farmacêutica, uso do anticorpo ou fragmento de ligação a anticorpo, método para tratar câncer, método para diagnosticar câncer em um indivíduo, anticorpo, método, composição ou uso
MX2023002554A (es) Anticuerpos anti-il-1r3 humanizados.
MX2016014753A (es) Tratamiento de cancer de pulmon con el uso de una combinacion de un anticuerpo de muerte anti-programada 1 (anti-pd-1) y otro agente anti-cancerigeno.
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
MX2024013016A (es) Anticuerpos anti-pd1 para usarse en el tratamiento del cancer
MY176475A (en) Human antibodies to pd-1
MX2020006116A (es) Terapia combinada de agonistas de icos dirigidos a tumores con moleculas biespecificas de linfocitos t.
EA200970317A1 (ru) Комбинированное лечение опухолей, экспрессирующих cd38
ZA202202363B (en) Antibodies against ilt2 and use thereof
MX2021007350A (es) Terapia combinada de cd70 y venetoclax, un inhibidor de bcl-2, para tratar la leucemia mieloide aguda.
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
EA202090741A1 (ru) Конъюгаты антитела к тканевому фактору и лекарственного средства и их применение в лечении рака
ZA201907754B (en) Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
EA201992318A1 (ru) Композиции и способы для диагностики и лечения рака предстательной железы с использованием молекулы, связывающей прогастрин
BR112017011538A2 (pt) combinação de anticorpos anti-cs1 e anti-pd1 para tratar câncer (mieloma)
HK1252514A1 (zh) 包含与抗体组合施予的ido抑制剂的肿瘤治疗剂
EA201991870A1 (ru) Лечение рака мочевого пузыря с помощью антитела к pd-l1
BR112022001037A2 (pt) Métodos para tratamento ou prevenção de cânceres envolvendo a administração de agentes receptores anti-ccr5
BR112016023011A2 (pt) tratamento de câncer gástrico